Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Phase II Study of Chemotherapy and Immune Checkpoint Blockade with Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma

Clinical Trial Details

This clinical trial is for men and women with gastric or gastroesophageal junction adenocarcinoma. 

The purpose of this study is to determine the effectiveness of combining immune therapy with standard chemotherapy. 

You will receive the study treatment - 5-FU or Capecitabine, Oxaliplatin, and Epirubicin and Pembrolizumab, for 9-12 weeks followed by surgery and a 9 week post-operative period of Pembrolizumab and standard of care chemotherapy. You will then receive long-term therapy with Pembrolizumab for up to 12 months following surgery. After you finish this treatment, your doctor will continue to watch you for side effects and follow your condition for up to 90 days. 

The estimated duration for which you are going to be on the study is 16 months. After that, the study team will contact you by phone every 12 weeks to check how you are doing. 

Key Eligibility: 

- Open to men and women age 18 and older 
- Gastric or gastroesophageal junction adenocarcinoma diagnosis
- Detailed eligibility will be reviewed when you contact the study team 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Carina Puello, RN
(646) 962-3541
cap4008@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1706018329

Status

Open to Enrollment

Age Group

Adult

Sponsor